Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211808 · ClinicalTrials.gov registry record · Phase 1
Effect of Diltiazem on Pharmacokinetics of BMS-914392
A Phase 1 study of Atrial Fibrillation, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01211808: Completed Phase 1 study of Atrial Fibrillation, sponsored by Bristol-Myers Squibb.
NCT01211808 is a Phase 1 study of Atrial Fibrillation that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01211808, a Phase 1 study of Atrial Fibrillation, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
Conditions Studied
Interventions
- DRUG Diltiazem
- DRUG BMS-914832
Study Locations (1)
Kansas
- Pra International - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-09 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
What the finished NCT01211808 record still lists
NCT01211808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,997-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Diltiazem is the first listed.
NCT01211808 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01211808 about?
NCT01211808 is a clinical study titled "Effect of Diltiazem on Pharmacokinetics of BMS-914392". The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.
What is the current status of trial NCT01211808?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-09. Estimated completion is 2010-10.
What conditions does trial NCT01211808 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT01211808?
The interventions under investigation include: Diltiazem (DRUG), BMS-914832 (DRUG).
Who is sponsoring clinical trial NCT01211808?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01211808 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01211808's enrollment target sits among peer trials
24 191st of 202 higher than 12 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Synaptic Plasticity in the Epicardial Ganglionated Plexi
RECRUITING · Phase 1
-
Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study
COMPLETED · Phase 1
-
Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
COMPLETED · Phase 1
-
Stroke Feasibility Study
COMPLETED · Phase 1
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia